[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100121861":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":23,"centralContacts":10,"locations":27,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":10,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"A",null,[12],"Drug: activated recombinant human factor VII",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","activated recombinant human factor VII","Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice",[9],[20,21,22],"NovoSeven®","rFVIIa","F7",[24],{"name":25,"affiliation":5,"role":26},"Global Clinical Registry (GCR, 1452)","STUDY_DIRECTOR",[28],{"facility":29,"status":10,"city":30,"state":10,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"Novo Nordisk Investigational Site","Crawley","RH11 9RT","United Kingdom","UK",{"type":35,"coordinates":36},"Point",[37,38],-0.18312,51.11303,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100121861","post-marketing-safety-surveillance-of-novoseven-in-patients-with-haemophilia-and-inhibitors-by-means-of-the-uk-haemophilia-database-100121861",false,"NCT00853086","Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database","United Kingdom Haemophilia Centre Doctor's Organisation (UKHCDO) - Novo Nordisk Collaboration on NovoSeven® Post Marketing Follow-up Measures","Inclusion Criteria:\n\n* All haemophilia A or B patients with inhibitors treated with NovoSeven are included\n\nExclusion Criteria:\n\n* No exclusion criteria beyond the contraindications described in the approved product information text","MALE",{"count":51,"type":52},139,"ACTUAL","OBSERVATIONAL","This study is conducted in Europe. The purpose of this retrospective study is to collect additional safety information of patients with haemophilia and inhibitors who are treated with rFVIIa.",[56,57,58],"Congenital Bleeding Disorder","Haemophilia A","Haemophilia B","COMPLETED","2016-11-15",{"date":62,"type":63},"2016-11-16","ESTIMATED",{"date":65,"type":10},"2008-01",{"date":67,"type":52},"2011-06",{"name":5,"class":6},1]